{"id":"W3005910897","doi":"10.1016/j.jaad.2020.02.009","title":"Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Janssen Biotech; Genentech; Bausch Health; MedImmune; Sanofi; Kyowa Hakko Kirin; InflaRx; Pfizer; Incyte; Dermira; Astellas Pharma Canada; Coherus Biosciences; Valeant Pharmaceuticals International; Galderma; UCB; Regeneron Pharmaceuticals; Novartis; Celgene; LEO Pharma; Gilead Sciences; GlaxoSmithKline; Merck; Roche; Baxalta; AbbVie; Genzyme; Amgen; Meiji Seika Pharma; Bristol-Myers Squibb","keywords":"Medicine; Atopic dermatitis; Dose-ranging study; Ruxolitinib; Randomized controlled trial; Dermatology; Quality of life (healthcare); Internal medicine; Alternative medicine; Double blind","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004498535,0.0001889043,0.003225254,0.0002008735,0.00003078346,0.000003329377,0.0002023985,0.000105864,0.000004393149],"category_scores_gemma":[0.005581983,0.0001234438,0.0002907864,0.0002116698,0.001040667,0.00007826099,0.00007765015,0.0005158941,3.462088e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001156747,"about_ca_system_score_gemma":0.0001072091,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001094441,"about_ca_topic_score_gemma":0.000002503129,"domain_scores_codex":[0.9954078,0.002029369,0.00189064,0.0001853808,0.0003000884,0.0001867472],"domain_scores_gemma":[0.9918903,0.004667709,0.003047003,0.0001212614,0.00006806717,0.0002057093],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6203057,0.004468922,0.3533074,0.001076303,0.002975852,0.0003042873,0.008035607,0.00001046089,0.006064415,0.000196081,0.000814112,0.002440907],"study_design_scores_gemma":[0.4354573,0.000552585,0.5526177,0.00034298,0.0007713364,0.0002097696,0.00113891,0.0001719441,0.008311915,0.0003027689,0.00002898583,0.00009386552],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9831703,0.002821896,0.000009745191,0.01291098,0.00003584049,0.0009537429,0.00003993182,0.000005771944,0.00005183261],"genre_scores_gemma":[0.996628,0.0005151528,0.0001033437,0.002691348,0.00003649385,0.00001225672,0.000001118373,0.00001039477,0.000001899172],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1993102,"threshold_uncertainty_score":0.6682558,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02069198284076659,"score_gpt":0.331547145434567,"score_spread":0.3108551625938004,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}